SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is drawing attention amid the boards investigation into CEO Jensen Huang and allegations that his relationship involved a woman with ties to Chinese intelligence, alongside concerns about possible chip-control violations and a shareholder lawsuit. Traders are split between fearing leadership and legal fallout could prolong the selloff and viewing it as an overreaction that leaves Nvidias AI-chip business intact.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Reports that Microsoft is winding down rented AI-computing capacity and declining data-center expansion options have fueled concern that its AI infrastructure spending is slowing. Traders debate whether this signals strain in AI demand and pressure on cash flow, or simply a shift toward newer capacity and Microsoft-owned data centers.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,110,071. The last known price of Bitcoin is 74,895.40905656 USD and is down -0.28 over the last 24 hours. It is currently trading on 12776 active market(s) with $26,892,693,016.04 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Hotter-than-expected U.S. inflation has strengthened expectations for further Fed rate hikes, adding pressure to Bitcoin alongside other risk assets; reports of leveraged long liquidations have intensified the selloff. Traders are divided between expecting more downside and viewing the decline as an oversold buying opportunity near technical support.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is under pressure after a disappointing Q3 report, with a surprise loss, weaker margins, a sequential subscriber decline, and reduced earnings guidance driving heavy selling. Traders are divided between concerns about profitability and subscriber momentum and hopes that the Peptides+ launch and broader growth plans could support a recovery.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,957,873.22986632. The last known price of Zcash is 1,170.00468254 USD and is down -4.93 over the last 24 hours. It is currently trading on 669 active market(s) with $1,123,501,581.28 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

A sharp Zcash selloff and break of technical support are dominating discussion, with traders pointing to crypto-market liquidations and broader risk-off pressure but also questioning the suddenness of the move. The community is split between expecting further downside and treating the pullback as a buying opportunity, citing Zcashs privacy-focused thesis and past resilience.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

A Goldman Sachs upgrade to Buy, alongside several analyst target increases, has fueled Zeta Globals push to a 52-week high after its strong earnings beat and raised guidance. Traders are broadly bullish on the growth outlook, though some flag overbought conditions and resistance after the sharp run-up.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

TTDs Q3 earnings beat and stronger Q4 outlook sparked a sharp after-hours rally, but the stock gave back much of the move after managements cautious tone. Traders are split between viewing the results and buyback authorization as signs of a turnaround or treating the reaction as a sell-the-news move amid weak underlying growth, margin pressure, and questions about whether the buyback will be used.

Digital Turbine, Inc. engages in mobile growth platform solutions for advertisers, publishers, carriers, and device original equipment manufacturers. It operates through the following segments: On Device Solutions and App Growth Platform. The On Device Solutions segment consists of products and services that simplify the discovery and delivery of mobile apps and content media for device end users. The App Growth Platform segment provides Advertising Solutions and Ad Monetization Solutions. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

Digital Turbines earnings triggered a sharp selloff despite a revenue beat and raised sales outlook, as gross-margin compression and unchanged EBITDA guidance raised concerns about whether growth is translating into profitability. Traders are divided between calling the decline an overreaction and pointing to margin pressure, debt, and dilution risks.

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

ASTS is under pressure after its quarterly results and analyst price-target cuts, with traders focused on launch delays, the slower path to commercial service, and the execution and spending risks of its planned rocket program. Bulls point to funding, government and telecom opportunities, and manufacturing progress, but the main debate is whether the company can launch enough satellites on schedule.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis Corp 

Trulieves quarterly results drew mixed reactions, with traders praising margins and cash generation while questioning weaker revenue and the medical-heavy business mix. The broader discussion centers on the pending DEA Schedule III process and potential 280E tax relief: some see Trulieves medical exposure as an advantage, while others remain wary of delays and uncertain reform prospects.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)PR NewswireNEW YORK, Oct. 12, 2026NEW YORK, Oct. 12...

The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte

Four biotech companies face key fall readouts that could influence the development and commercial prospects of their pipelines.

CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’

Equity

H.C. Wainwright called the Phase 3 results a “compelling” late-stage assessment of Barzolvolimab in a patient population with a significant unmet need.

4 Biotech Stocks With Key Clinical Readouts Expected This Fall

KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX) PR Newswire NEW YORK, Aug. 24, 2026 NEW YORK, Aug...

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of +9.62% and -98.75%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Are Medical Stocks Lagging  Celldex Therapeutics (CLDX) This Year?

Here is how Celldex Therapeutics (CLDX) and Illumina (ILMN) have performed compared to their sector so far this year.

CLDX Stock Down 10% After-Hours — What’s Driving The Selloff?

Celldex announced that its experimental drug barzolvolimab missed key goals in a mid-stage study for prurigo nodularis. 

Eton Pharmaceuticals (ETON) Moves 13.8% Higher: Will This Strength Last?

Eton Pharmaceuticals (ETON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval?

Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval...

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Celldex Therapeutics Inc.

Bullish Sentiment

<ul class="summary-bullets"><li>The brokerage raised the price target on Celldex to $64 from $42 and maintained a ‘Buy’ rating, according to The Fly.</li><li>Celldex’s Phase 3 studies met their primary and all key secondary endpoints for Barzolvolimab in chronic spontaneous urticaria.</li><li>The biotech firm plans to submit a BLA to the FDA in 2027.</li></ul>Celldex Therapeutics (CLDX) received a major price target hike on Tuesday, despite the stock crashing nearly 20%, after its experimental treatment for a skin condition delivered positive results in two late-stage studies.H.C. Wainwright raised the price target on Celldex to $64 from $42 and maintained a ‘Buy’ rating, according to The Fly. The updated target implies a nearly 90% upside from current levels.<h2 class="st-heading-2">Barzolvolimab Meets All Key Goals</h2>Celldex said both Phase 3 Embarq-CSU1 and Embarq-CSU2 studies of Barzolvolimab met their primary and all key secondary endpoints at 12 weeks. The drug is being developed for the treatment of chronic spontaneous urticaria (CSU), a skin condition that causes recurring hives and swelling.At Week 12, about 42% to 46% of patients receiving Barzolvolimab achieved a complete response, meaning they experienced no hives or itching, compared with roughly 9% to 13% of patients receiving placebo.Results strengthened further by Week 24, with complete response rates reaching 54%. The studies enrolled 1,939 patients.Celldex plans to file the Biologics License Application (BLA) with the FDA in 2027.Despite the results, <a href="https://stocktwits.com/symbol/CLDX">CLDX shares</a> initially plunged nearly 20% before trimming losses. At the time of writing, the stock traded around 11% lower.<h2 class="st-heading-2">Why Did CLDX Stock Slump Despite Positive Data?</h2>Despite the strong efficacy results, investors focused on the study’s safety data. Two cases were classified as probable Grade 4 anaphylaxis, a severe and potentially life-threatening allergic reaction to the drug. Celldex noted that one occurred after a placebo dose.H.C. Wainwright said the stock fell due to “misplaced focus/correction to announced safety metrics,” arguing that the Phase 3 results provide a “compelling, well-powered, controlled late-stage assessment” of Barzolvolimab in a patient population with significant unmet need.<h2 class="st-heading-2">Retail Split On Safety Data</h2>Despite the stock tanking, retail sentiment surrounding CLDX on Stocktwits flipped to ‘extremely bullish’ from ‘neutral’ over the past 24 hours, amid ‘extremely high’ message volumes.One user called the selloff an “overreaction.”<stembedurl>https://stocktwits.com/JayelesVentures/message/664788729</stembedurl>However, another user believes it’s a “classic sell the news event.”<stembedurl>https://stocktwits.com/TA_Kongen/message/664787362</stembedurl>The stock has gained more than 24% so far in 2026.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/msft-layoffs-microsoft-cuts-xbox-jobs/cZMPtYuRBeC">MSFT Layoffs: Microsoft Cuts 268 Xbox Jobs As Gaming Reset Deepens</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Celldex Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$CLDX  Increases price target to $64 from $42 yesterday. That is some confidence.... what does he know...

$CLDX  Oct. calls expired worthless. 1 month til the Nov. ones do too. Then might see some upward momentum

Feed

News

Sentiment

Earnings

Fundamentals

Info

CLDX Celldex Therapeutics Inc.

Fundamentals

Latest CLDX News